Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats

Journal of Pharmaceutical Sciences

Volumn 91, Issue 5, 2002, Pages 1324-1333

  Zara, Gian Paolo ^a   Bargoni, Alessandro ^a   Cavalli, Roberta ^a   Fundarò, Anna ^a   Vighetto, Daniela ^a   Gasco, Maria Rosa ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Biodistribution; Idarubicin; Idarubicinol; Plasma kinetics; Solid lipid nanoparticles

Indexed keywords

DRUG METABOLITE; IDARUBICIN; IDARUBICINOL; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SYNTHESIS; HEART; KIDNEY; LUNG; NONHUMAN; PARAMETER; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID; SPLEEN; TISSUE DISTRIBUTION;

EID: 0036073236     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10129     Document Type: Article

References (41)

1. Idarubicin: A review of its pharmacodynamic and pharmacokinetics properties and therapeutic potential in the chemotherapy of cancer
2. Pharmacokinetics of idarubicin following intravenous and oral administration in patients with advanced cancer
3. Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunorubicin
4. Antitumor activity of 4-demethoxydaunorubicin administered orally
5. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies
6. Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral dose
7. Clinical pharmacology of 4-demethoxydaunorubicin (DMDR)
8. Oral Idarubicin - A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer
9. Clinical pharmacokinetics of idarubicin
10. Idarubicin: A brief overview on pharmacological and clinical use
11. Plasma pharmacokinetics of cerebro-sinal fluid concentrations of idarubicin and idarubicinol in pediadric leukemia patients and children's cancer study group report
12. Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin
13. Solid lipid nanospheres from warm microemulsions
14. Thymopentin in solid lipid nanoparticles
15. NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing Gadolinium complexes
16. An x-ray examination of long-chain alkyldihydrogen phosphates and dialkylhydrogen phosphates and their sodium salts
17. Synthesis of daunorubicin analogues with novel 9-acyl substituent
18. Analysis of macromolecular polydispersity in intensity correlation spectroscopy: The method of cumulant
19. High performance liquid chromatographic determination of doxorubicin and its metabolites in plasma and tissue
20. Analysis of 4-demethoxydaunorubicin and metabolites in plasma and urine
21. Evaluation of nano- and microparticles uptake by the gastrointestinal tract
22. Factors affecting the oral uptake and traslocation of polystirene nanoparticles: Histological and analytical evidence
23. The transfer of polystyrene microspheres from the gastrointestinal tract to the circulation after oral administration in the rats
24. Improved peroral delivery of Avarol with polybutylcyanoacrylate nanoparticles
25. New approach for oral administration of insulin with polyalkyl cyanoacrilate nanocapsules as drug carrier
26. Body distribution of camptothecin solid lipid nanoparticles after oral administration
27. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art
28. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats
29. Transmucosal transport of tobramycin incorporated in SLN after duodenal administration to rats. Part I - A Pharmacokinetic study
30. Solid lipospheres of doxorubicin and idarubicin
31. Idarubicin overcomes P-glycoprotein-related multidrug resistance: Comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines
32. Cellular uptake and cytoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel
33. Current concepts: Doxorubicin-induced cardiomyopathy
34. Induction of apoptosis by idarubicin: How important is the plasma peak?
35. Apects of cytotoxic drug penetration with particular reference to anthracyclines
36. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier
37. Nanoparticulate systems for brain delivery of drugs
38. Biodistribution of stealth and non-stealth Solid Lipid Nanospheres after intravenous administration to rats
39. Non-stealth and stealth solid lipid nanoparticles carrying doxorubicin: Pharmacokinetics and tissue distribution after iv administration to rats
40. Passage of peptides through the blood brain barrier with colloidal polymer particles (nanoparticles)
41. Nanoparticle technology for delivery of drugs across the blood-brain barrier